Newsletter

Healthcare Stocks

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

There are plenty of ASX Biotech Targets that major pharmaceutical companies wanting to minimise the impact of the Patent Cliff could look at. For those who don't know what the patent cliff is, it is is one of the most consequential forces in global pharmaceuticals. The concept of a big pharma's drug losing exclusivity and having…

ByNick SundichMarch 16, 2026

Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?

After nearly a week in suspense, Immutep (ASX:IMM) confirmed news about Efti that its investors did not want to hear, and arguably feared more and more as the week with trading suspended went on. Namely, its most advanced clinical trial for Efti is all over red rover! While it is not the end of the company,…

ByNick SundichMarch 13, 2026

Orthocell (ASX: OCC) Lines Up UK Distributor for Remplir Ahead of Approval- Is Now the Time to Buy?

Orthocell Moves Closer to UK Growth Orthocell (ASX: OCC) just made a move that not every small-cap medtech company would make. Rather than waiting for regulatory approval before signing a UK distributor agreement, the company secured one early. On December 15, 2025, Orthocell submitted its application to the British Standards Institution seeking approval to sell…

ByUjjwal MaheshwariMarch 11, 2026

What does the 2026 health insurance premium rise mean for ASX health insurance stocks?

The 2026 health insurance premium rise is in, and it is 4.41%. It made headlines because it is ahead of inflation and the largest average increase in percentage terms since 2017. Obviously unwelcome timing for households struggling with the cost of living, but good for the companies themselves, right? Not so fast. What are the Best…

ByNick SundichMarch 10, 2026

Pro Medicus (ASX: PME) Falls Despite A$40m in US Renewals: Is This a Buying Opportunity?

Pro Medicus Dips Despite Strong Renewals Pro Medicus (ASX: PME) slipped around 1% on Monday despite announcing approximately A$40m in US contract renewals, including an expanded deal with MedStar Health and a third renewal from imaging group Zwanger-Pesiri at higher per-transaction fees. The pullback has nothing to do with the business itself. It is a…

ByUjjwal MaheshwariMarch 10, 2026

Nanosonics (ASX:NAN) Revenue Up 9%, But Operating Leverage Still Missing

Nanosonics Investors Want Margin Accretion, This Half Did Not Deliver It Nanosonics saw its share price fall 7% to around $3.35 today after what looked like a fairly moderate half year result. The business delivered broad based growth, but profitability was slightly softer, which is where the market seemed to focus. Here is the quick snapshot. …

ByCharlie YouldenFebruary 24, 2026

Here are 4 ASX biotechs with major milestones coming right up!

Investing in ASX biotechs is a risky business, even more than most other companies on the market. Unless you own one of the large cap biotechs, you are betting that major milestones (such as clinical trial completions and decisions on regulatory approval) will occur right on cue and that they will be favourable to the…

ByNick SundichFebruary 24, 2026

Is Fisher & Paykel Healthcare (ASX:FPH) a Buy After Upgrading Guidance? The Tariff Risk Investors Are Ignoring

Fisher & Paykel Healthcare (ASX: FPH) lifted its FY26 guidance on Monday, now expecting around NZ$2.30 billion in revenue and NZ$450 million to NZ$470 million in net profit. Both figures sit comfortably above what management guided three months ago, and the shares rose around 4% to A$32.91. Strong hospital product sales and better margins are…

ByUjjwal MaheshwariFebruary 24, 2026

Telix (ASX:TLX) Could Be A Turnaround Story (Investing for FY26)

Illuccix Still Prints, Gozellix Adds a New Growth Leg Telix saw a small rerate this morning after releasing its full year results, and for us it comes back to two core priorities the company is executing on. First, the imaging business is performing well. Illuccix, its main prostate imaging product, is continuing to show strong growth.…

ByCharlie YouldenFebruary 20, 2026

Alcidion (ASX:ALC) Wins Dual AI Healthcare Approval After Swinging to Profit- Time to Buy or Wait?

Alcidion Clears a Key AI Approval Hurdle Alcidion Group (ASX: ALC) hit a regulatory milestone that could open up its next phase of growth. The company has secured Class I Software as a Medical Device (SaMD) registration for the AI-powered concept detection feature inside its flagship Miya Precision platform, both in Australia and the United…

ByUjjwal MaheshwariFebruary 20, 2026

the Kick-ass Multipurpose WordPress Theme

Healthcare Stocks

Here are 5 ASX Biotech Targets Amidst The $230bn Patent Cliff; And Which Big Pharma Companies Could Buy Them!

Immutep’s Phase 3 trial for Efti has gotten the chop and shares plunge >90%! What now for investors?

Orthocell (ASX: OCC) Lines Up UK Distributor for Remplir Ahead of Approval- Is Now the Time to Buy?

What does the 2026 health insurance premium rise mean for ASX health insurance stocks?

Pro Medicus (ASX: PME) Falls Despite A$40m in US Renewals: Is This a Buying Opportunity?

Nanosonics (ASX:NAN) Revenue Up 9%, But Operating Leverage Still Missing

Here are 4 ASX biotechs with major milestones coming right up!

Is Fisher & Paykel Healthcare (ASX:FPH) a Buy After Upgrading Guidance? The Tariff Risk Investors Are Ignoring

Telix (ASX:TLX) Could Be A Turnaround Story (Investing for FY26)

Alcidion (ASX:ALC) Wins Dual AI Healthcare Approval After Swinging to Profit- Time to Buy or Wait?

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Healthcare Stocks

Stocks in Spotlight

Add Your Heading Text Here